



Clinical Center

CME SELF-REPORT CREDIT FORM

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Johns Hopkins University School of Medicine and the National Institutes of Health. The Johns Hopkins University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement:

The Johns Hopkins University School of Medicine designates this live activity for 1 credit per session for a maximum of 44 *AMA PRA Category 1 Credit(s)*TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.



Clinical Center Grand Rounds

Lipsett Amphitheater
12:00 Noon – 1:00 pm
June 1, 2016

Clinicopathologic Grand Rounds: Clinical Cases from the NIH Clinical Center

Pathologic Immune Responses to Co-infections in HIV: Two Rare Diseases, One Therapeutic Target

Maura M. Manion, MD, Clinical Fellow, HIV Pathogenesis Section, Laboratory of Immunoregulation, NIAID

Thomas S. Uldrick, MD, Senior Clinician, HIV and AIDS Malignancy Branch, Center for Cancer Research, NCI

Irini Sereti, MD, Chief, HIV Pathogenesis Section, Laboratory of Immunoregulation, NIAID

Stefania Pittaluga, MD, PhD, Staff Clinician, Laboratory of Pathology, NCI

Dima Hammoud, MD, Tenure Track Investigator, Center for Infectious Disease Imaging (CIDI), Neuroradiologist, Radiology and Imaging Services, CC

Note: To receive CME credit, this form must be completed and returned to the Office of Clinical Research Training and Medical Education by 6 pm on the day of the lecture. Please fax forms to 301-435-5275 or scan and email forms to daniel.mcanally@nih.gov. For CC Grand Rounds CME inquiries, contact Daniel McAnally 301-496-9425

Date(s)	Maximum Approved Hours per session/per week	Earned Hours
June 1, 2016	1 hour per session/per week	1.0*

Please Print Clearly

Please check one: Physician Non-Physician

NAME - LAST

FIRST

MI

PROFESSIONAL DEGREE

EMAIL (REQUIRED)

PHONE

ADDRESS

CITY

STATE

ZIP

SIGNATURE REQUIRED for ALL ATTENDEES:

I attest that the above number credit hour(s) is correct.

X _____
Signature of Attendee

Date

*These hours will be verified by the Office of Continuing Medical Education (OCME) and recorded on your official Transcript.



FULL DISCLOSURE POLICY AFFECTING CME ACTIVITIES

Clinical Center Grand Rounds

Lipsett Amphitheater
Bethesda, Maryland
June 1, 2016

As a provider approved by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of the Johns Hopkins University School of Medicine Office of Continuing Medical Education (OCME) to require signed disclosure of the existence of financial relationships with industry from any individual in a position to control the content of a CME activity sponsored by OCME. Members of the Planning Committee are required to disclose all relationships regardless of their relevance to the content of the activity. Speakers are required to disclose only those relationships that are relevant to their specific presentation. The following relationships have been reported for this activity:



SPEAKERS NAME AND LECTURE TITLES

RELATIONSHIP(S)

Pathologic Immune Responses to Co-infections in HIV: Two Rare Diseases, One Therapeutic Target

Dima Hammoud, MD

Maura M. Manion, MD

Thomas S. Uldrick, MD

Irini Sereti, MD

Stefania Pittaluga, MD, PhD

No speaker has indicated that they have any financial interests or relationships with a commercial entity whose products or services are relevant to the content of their presentations.

No planner has indicated that they have any financial interests or relationships with a commercial entity.

Note: Grants to investigators at the Johns Hopkins University are negotiated and administered by the institution which receives the grants, typically through the Office of Research Administration. Individual investigators who participate in the sponsored project(s) are not directly compensated by the sponsor, but may receive salary or other support from the institution to support their effort on the project(s).

OFF-LABEL PRODUCT DISCUSSION

The following speakers have disclosed that their presentation will reference unlabeled/unapproved uses of drugs or products:

NAME AND LECTURE(S)

Product

Maura M. Manion, MD; Thomas S. Uldrick, MD; Irini Sereti, MD

Pathologic Immune Responses to Co-infections in HIV:
Two Rare Diseases, One Therapeutic Target

rituximab, valganciclovir, zidovudine,
prednisone, infliximab, tocilizumab

No other speaker has indicated that they will reference unlabeled/unapproved uses of drugs or products.

EVALUATION FORM
Clinical Center Grand Rounds at the National Institutes of Health
June 1, 2016

Please complete the Continuing Medical Education Questionnaire. To indicate your answers, use the rating scale that is shown by circling the number that represents your answer.

Scale: 1 - None or Not at all 2 - Very little 3 - Moderately 4 - Considerably 5 - Completely N/A - Not applicable

Speakers: Maura M. Manion, MD; Thomas S. Uldrick, MD; Irini Sereti, MD; Stefania Pittaluga, MD, PhD; Dima Hammoud, MD
Objective: To describe the clinical and diagnostic features of paradoxical immune reconstitution inflammatory syndrome (IRIS) related to tuberculosis (TB). To describe the clinical and diagnostic features of KSHV-associated multicentric Castleman disease (KSHV-MCD). To describe the role of inflammatory cytokines in TB-IRIS and KSHV-MCD pathogenesis, and the potential utility of IL-6 blockade in both of these HIV-associated conditions.

A. Rating of Objectives and Activity

1. Please rate the attainment of objectives:

- | | | | | | | |
|---|---|---|---|---|---|-----|
| a. Define options and alternatives that will guide clinical practice | 1 | 2 | 3 | 4 | 5 | N/A |
| b. Evaluate practical information about clinical research principles based on state-of-the-art information about scientific discovery and clinical advances | 1 | 2 | 3 | 4 | 5 | N/A |
| c. Analyze information and opportunities to increase and improve collaboration between investigators | 1 | 2 | 3 | 4 | 5 | N/A |

2. The overall quality of the instructional process was an asset to the activity: 1 2 3 4 5 N/A

3. To what extent did participation in this activity enhance your professional effectiveness? 1 2 3 4 5 N/A

4. Will you change your practice in any way as a result of attending this activity? 1 2 3 4 5 N/A

5. Did you perceive any commercial bias?
Use the following criteria to judge?

- a) The content presented was balanced, evidence-based, demonstrated scientific rigor, and was without commercial bias. No Yes
If no, please specify: _____
- b) I was informed about the existence and resolution of relevant financial relationships/conflicts of interests of planners and presenters prior to the presentation. No Yes
If no, please specify: _____
- c) Speakers who discussed off-label, investigational, or alternative uses of products, devices, or techniques disclosed this in their presentation. No Yes
If no, please specify: _____

B. Comments:

1. What comments or suggestions do you have for the faculty presenter(s)?

2. Are there any other speakers or new topics you would like to have covered in this or a related activity?

3. Do you have additional comments to enhance the utility or impact of the activity?

4. May we contact you in several weeks' time with a very brief survey to assess the usefulness of this CME activity? Yes No If yes, please provide your email: _____